Welcome to our dedicated page for Paragon 28 news (Ticker: FNA), a resource for investors and traders seeking the latest updates and insights on Paragon 28 stock.
Paragon 28, Inc. (NYSE: FNA) is a medical device company based in Englewood, Colorado and exclusively focused on the foot and ankle orthopedic market. This news page aggregates coverage related to the company’s specialized implants, instrumentation and digital tools for foot and ankle surgery, as well as key corporate and regulatory developments.
Readers can find updates on Paragon 28’s participation in major professional meetings such as the American College of Foot and Ankle Surgeons (ACFAS) Annual Scientific Conference and the American Academy of Orthopaedic Surgeons (AAOS) Annual Conference. News from these events often highlights recently launched products, including systems for total ankle replacement, fibula fracture stabilization, syndesmotic repair, minimally invasive bunion correction and single-use power systems for foot and ankle procedures.
Coverage also includes announcements about Paragon 28’s digital initiatives, such as the SMART 28℠ Case Management Portal featuring SMART Bun-Yo-Matic℠, a platform described as integrating AI, data analytics and 3D modeling to streamline surgical planning and execution. Corporate news items may address preliminary revenue updates, conference presentations, board appointments and legal or shareholder-related matters.
In addition, this page features transaction-related news, including the definitive agreement for Zimmer Biomet Holdings, Inc. to acquire Paragon 28 and subsequent regulatory milestones like the expiration of the Hart-Scott-Rodino Act waiting period. By reviewing these articles, investors and observers can follow how Paragon 28’s product launches, strategic initiatives and proposed corporate transactions shape its role in the foot and ankle orthopedic segment over time.
Paragon 28 (NYSE: FNA), a prominent medical device company specializing in the foot and ankle orthopedic market, has appointed B. Kristine Johnson and Kristina Wright to its Board of Directors, effective December 1, 2021. Johnson, with extensive experience in med-tech leadership and strategy, aims to enhance commercial growth, while Wright brings strong finance and corporate development expertise. CEO Albert DaCosta expressed confidence in their ability to drive future growth and innovation in the company.
Paragon 28, Inc. (NYSE: FNA), a leader in orthopedic devices for the foot and ankle, announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference. Chairman and CEO Albert DaCosta and CFO Steve Deitsch will present virtually on November 30 and December 1. A pre-recorded fireside chat will be available for on-demand viewing starting November 24, 2021, at 8:00am MT / 10:00am ET, with the webcast accessible via the company’s investor relations website.
Paragon 28, Inc. (NYSE: FNA) reported a strong performance for Q3 2021, showing net revenue of $35.9 million, an increase of 18% year-over-year. For the nine-month period ending September 30, total revenue reached $104.7 million, up 38% compared to 2020. The company achieved a gross margin of 80.2%, an improvement over the previous year's 76.7%. Despite these gains, Paragon reported a net loss of $5.1 million in Q3 2021, compared to a $3.8 million profit in Q3 2020. The company expects Q4 revenue guidance between $38.0 million and $39.0 million, indicating continued growth.
Paragon 28, Inc. (NYSE: FNA) has received 501(k) marketing clearance from the FDA for its Circular External Fixation System, set to launch commercially in early 2022. This marks the company's first external fixation product and will expand its existing internal fixation portfolio in the foot and ankle orthopedic sector. Brendan Shook, Executive VP of Marketing, expressed enthusiasm about the new product, which aims to improve patient outcomes in foot and ankle care.
Paragon 28, Inc. (NYSE: FNA) will announce its third quarter 2021 financial results on November 22, 2021, before the market opens. A conference call is scheduled for 8:30 a.m. Eastern Time the same day, with participation available via phone and online webcast. Investors can access the live audio on the company's website, and a replay will be available for 90 days. This upcoming report will provide key insights into the company's performance in the foot and ankle orthopedic market.
Paragon 28, Inc. (NYSE: FNA) has priced its initial public offering (IPO) of 7,812,500 common shares at $16.00 each, aiming for gross proceeds of $125 million. Trading on the NYSE is set to commence on October 15, 2021, with the offering expected to close on October 19, 2021. A 30-day option for underwriters to purchase an additional 1,171,875 shares at the offering price is also available. The offering process follows effective registration by the U.S. Securities and Exchange Commission on October 14, 2021.